Arvinas Stock News

NEW HAVEN, Conn., June 02, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today anno

The stock price of Arvinas (NASDAQ: ARVN), a biopharmaceuticals company focused on oncology treatments based on targeted protein degradation, has fallen 24% in a month, while it's down a significant 4

Arvinas announced decent data from ARV-110 in February. The market may have expected more.

Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -41.18% and 23.55%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Over the past 3 months, 6 analysts have published their opinion on Arvinas (NASDAQ:ARVN) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company

Upgrades According to Johnson Rice, the prior rating for RPC Inc (NYSE:RES) was changed from Hold to Accumulate. In the first quarter, RPC showed an EPS of $0.07, compared to $0.05 from the year-ago

Arvinas, Inc. (ARVN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Arvinas, Inc. (ARVN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Arvinas (NASDAQ:ARVN) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 2 1 0 0 Last 30D 0 0

Upgrades According to Morgan Stanley, the prior rating for Royalty Pharma PLC (NASDAQ:RPRX) was changed from Equal-Weight to Overweight. In the fourth quarter, Royalty Pharma showed an EPS of $0.80, c

Arvinas Inc. (NASDAQ:ARVN) shares, rose in value on Friday, 03/11/22, with the stock price down by -0.53% to the previous day’s close as strong demand from buyers drove the stock to $68.21. Actively observing the price movement in the last trading, the stock closed the session at $68.57, falling within a range of $67.685 and … Things To Consider Before Buying Arvinas Inc. (NASDAQ: ARVN) Read More »

NEW HAVEN, Conn., March 04, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today a

NEW HAVEN, Conn., March 04, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ann

Epizyme (EPZM) posts a wider-than-expected loss for the fourth quarter. Revenues also miss estimates. Nevertheless, the pipeline progress is encouraging.

Axsome Therapeutics (AXSM) reports a narrower-than-expected Q4 loss. The company is actively preparing to support the commercial launch of its two under-review candidates, AXS-05 and AXS-07.